|Bid||436.700 x 800|
|Ask||437.120 x 900|
|Day's Range||432.070 - 441.680|
|52 Week Range||139.490 - 446.810|
|PE Ratio (TTM)||178.87|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||388.89|
ResMed's (RMD) wholly owned unit Brightree remains integral to the company's group for two full years with a consistent stretch of success.
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
Cardinal Health (CAH) intends to boost its acute-care program platform by jointly investing in the earlier acquired naviHealth along with Clayton, Dubilier & Rice.
Wright Medical's (WMGI) AUGMENT Injectable Bone Graft platform has same clinical indications as the company's flagship AUGMENT Bone Graft.
Abiomed Inc. investors celebrated as the stock more than tripled over the last year. “There aren’t a lot of alternatives that physicians have to this technology and there’s really no competition,” Denhoy, who boasts a Street-high target of $460, said in a telephone interview. Abiomed may continue the trend of medical device and technology companies overtaking the top spot in the S&P 500 after Align Technology Inc. topped the index in 2017.
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Discovery, Inc. DISCA : "Yes, I do [think their content is undervalued].
The outlook for growth stocks looks good, especially for technology and health care stocks. Here's why.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.
Who Is Eyeing Abiomed in 2018? In its first-quarter conference call, Abiomed (ABMD) declared that it had almost completed the enrollment of 46 patients out of the total 50 patients in the FDA-approved feasibility study. This study aims to evaluate the possibility of using Impella CP heart pump for unloading the left ventricle for patients who have been suffering from ST segment elevation myocardial infarction (or STEMI) without cardiogenic shock and who would be undergoing a primary percutaneous coronary intervention (or PCI) procedure.
Who Is Eyeing Abiomed in 2018? On February 14, Abiomed (ABMD) announced that its Impella 2.5 and Impella CP heart pumps had secured approval from the FDA to be used for providing temporary ventricular support in urgent and elective high-risk percutaneous coronary intervention (or PCI) procedures. This approval has expanded Impella’s initial label, which required patients with complex anatomy or coronary artery disease and undergoing high-risk PCI procedures to have depressed ejection fraction.
Who Is Eyeing Abiomed in 2018? By the end of fiscal 2018, Abiomed’s (ABMD) Impella attained a penetration rate of 9.0% of the eligible 231,000 patients in the United States. In addition to increasing the market penetration of the Impella line of devices in the United States in fiscal 2019, the company is focused on the increasing adoption of these devices in Germany and Japan, which have 25,000 and 50,000 Impella eligible patients, respectively.
In the fiscal fourth quarter, Abiomed (ABMD) reported worldwide Impella heart pump sales of ~$168.3 million, which is a year-over-year (or YoY) rise of ~42.0%. The company reported fiscal 2018 Impella heart pump sales of ~$570.9 million, which is a YoY rise of ~35.0%.
Regulatory issues regarding Onrad, intense competition in the radiation oncology market and unfavorable foreign exchange rate are significant challenges for Accuray (ARAY).